We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BSX Set to Report Q3 Earnings: Will MedSurg Strength Aid Performance?
Read MoreHide Full Article
Key Takeaways
Boston Scientific's Q3 2026 revenues are projected to rise 2.1% to $5.17 billion, while EPS may grow 1.3%.
BSX's MedSurg may gain from Endoscopy, Neuromodulation and Nalu Medical amid ongoing Urology pressures.
BSX's Cardiovascular unit may have benefited from imaging, embolization tech and vascular portfolio growth.
Boston Scientific Corporation (BSX - Free Report) is slated to report third-quarter 2026 results on Oct. 28, before the market opens.
The renowned medical device manufacturer posted earnings per share (EPS) of 86 cents in the last reported quarter, which surpassed the Zacks Consensus Estimate by 3.61%. The company topped earnings estimates in three of the trailing four quarters and broke even once, the average surprise being 2.95%.
BSX’s Q3 Estimates
For the third quarter of 2026, the Zacks Consensus Estimate for Boston Scientific’s revenues is pegged at $5.17 billion, indicating an increase of 2.1% from the year-ago reported figure.
The Zacks Consensus Estimate for the company’s third-quarter EPS suggests a 1.3% rise to 76 cents. The estimate has dropped 5% in the past 30 days.
Let’s briefly review the company’s performance leading up to this announcement.
What May Have Influenced BSX’s Q3 Performance?
MedSurg
In the third quarter of 2026, the segment may have contributed due to continued strength in Endoscopy and Neuromodulation. Endoscopy sales are likely to have gained from the biliary franchise, led by the AXIOS Stent and Delivery System, and the core gastrointestinal (GI) franchise. Boston Scientific also secured FDA clearance for RIVOS, a first-of-its-kind single device designed to consolidate multiple exchanges, allowing physicians to streamline procedural steps while performing endoscopic ultrasound biliary drainage. Initial cases had received positive feedback.
Neuromodulation is likely to have benefited from the strength of its comprehensive pain portfolio, led by the Intracept Intraosseous Nerve Ablation System. The acquired Nalu Medical may have provided another quarter of solid sales contribution, with integration efforts continuing. In the brain franchise, Boston Scientific’s global growth may have been favorably supported by the continued adoption of the Cartesia X leads and accelerating uptake of the Illumina 3D programming algorithm in the United States.
Boston Scientific Corporation Price and EPS Surprise
Meanwhile, similar to the previous quarter, Urology may have faced continued headwinds from weakness in the stone franchise due to volume-based procurement in China and commercial disruption in sacral neuromodulation.
The Zacks Consensus Estimate projects MedSurg revenues to increase 1.6% year over year in the third quarter.
Cardiovascular
In the third quarter of 2026, Boston Scientific may have faced continued weakness in two historically strong Cardiovascular businesses. During the July earnings call, management lowered its full-year organic revenue and profitability outlook, citing a more challenging second half of 2026 than previously expected. WATCHMAN sales were hurt by an unexpected slowdown in the U.S. market, as compounding clinical evidence impacted referral patterns. In Electrophysiology (“EP”), the level of competitive share movement in the U.S. market was greater than anticipated.
The Cardiac Rhythm Management (“CRM”) business may remain a drag on the quarter’s results, reflecting continued competitive pressures and gaps within the product portfolio. Weakness across its low-voltage and high-voltage businesses is likely to have persisted. On a positive note, strength across the company’s broad diagnostic portfolio may have helped offset some of the pressures.
Boston Scientific is also expected to have seen sustained momentum in its Interventional Cardiology business, driven by continued strength in DCB, imaging and complex PCI. Vascular Therapies results may benefit from broader adoption of Varithena and the drug-eluting portfolio. Following strong reception of the SEISMIQ IVL device for its clinical differentiation, the company is likely to have continued to ramp up its supply.
Interventional Oncology and Embolization is also expected to have delivered strong global growth, aided by demand for its broad range of technologies.
According to the Zacks Consensus Estimate, Cardiovascular revenues are expected to see a 0.7% decline from the prior-year period.
What Our Model Unveils for BSX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.
Earnings ESP: Boston Scientific has an Earnings ESP of -3.63%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Phibro Animal Health (PAHC - Free Report) has an Earnings ESP of +2.10% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2027 results soon.
PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2.
IDXX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company’s third-quarter EPS implies a jump of 9.1% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) , or BD, has an Earnings ESP of +3.28% and a Zacks Rank #2. The company will release its fourth-quarter fiscal 2026 results on Nov. 5.
BD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
BSX Set to Report Q3 Earnings: Will MedSurg Strength Aid Performance?
Key Takeaways
Boston Scientific Corporation (BSX - Free Report) is slated to report third-quarter 2026 results on Oct. 28, before the market opens.
The renowned medical device manufacturer posted earnings per share (EPS) of 86 cents in the last reported quarter, which surpassed the Zacks Consensus Estimate by 3.61%. The company topped earnings estimates in three of the trailing four quarters and broke even once, the average surprise being 2.95%.
BSX’s Q3 Estimates
For the third quarter of 2026, the Zacks Consensus Estimate for Boston Scientific’s revenues is pegged at $5.17 billion, indicating an increase of 2.1% from the year-ago reported figure.
The Zacks Consensus Estimate for the company’s third-quarter EPS suggests a 1.3% rise to 76 cents. The estimate has dropped 5% in the past 30 days.
Let’s briefly review the company’s performance leading up to this announcement.
What May Have Influenced BSX’s Q3 Performance?
MedSurg
In the third quarter of 2026, the segment may have contributed due to continued strength in Endoscopy and Neuromodulation. Endoscopy sales are likely to have gained from the biliary franchise, led by the AXIOS Stent and Delivery System, and the core gastrointestinal (GI) franchise. Boston Scientific also secured FDA clearance for RIVOS, a first-of-its-kind single device designed to consolidate multiple exchanges, allowing physicians to streamline procedural steps while performing endoscopic ultrasound biliary drainage. Initial cases had received positive feedback.
Neuromodulation is likely to have benefited from the strength of its comprehensive pain portfolio, led by the Intracept Intraosseous Nerve Ablation System. The acquired Nalu Medical may have provided another quarter of solid sales contribution, with integration efforts continuing. In the brain franchise, Boston Scientific’s global growth may have been favorably supported by the continued adoption of the Cartesia X leads and accelerating uptake of the Illumina 3D programming algorithm in the United States.
Boston Scientific Corporation Price and EPS Surprise
Boston Scientific Corporation price-eps-surprise | Boston Scientific Corporation Quote
Meanwhile, similar to the previous quarter, Urology may have faced continued headwinds from weakness in the stone franchise due to volume-based procurement in China and commercial disruption in sacral neuromodulation.
The Zacks Consensus Estimate projects MedSurg revenues to increase 1.6% year over year in the third quarter.
Cardiovascular
In the third quarter of 2026, Boston Scientific may have faced continued weakness in two historically strong Cardiovascular businesses. During the July earnings call, management lowered its full-year organic revenue and profitability outlook, citing a more challenging second half of 2026 than previously expected. WATCHMAN sales were hurt by an unexpected slowdown in the U.S. market, as compounding clinical evidence impacted referral patterns. In Electrophysiology (“EP”), the level of competitive share movement in the U.S. market was greater than anticipated.
The Cardiac Rhythm Management (“CRM”) business may remain a drag on the quarter’s results, reflecting continued competitive pressures and gaps within the product portfolio. Weakness across its low-voltage and high-voltage businesses is likely to have persisted. On a positive note, strength across the company’s broad diagnostic portfolio may have helped offset some of the pressures.
Boston Scientific is also expected to have seen sustained momentum in its Interventional Cardiology business, driven by continued strength in DCB, imaging and complex PCI. Vascular Therapies results may benefit from broader adoption of Varithena and the drug-eluting portfolio. Following strong reception of the SEISMIQ IVL device for its clinical differentiation, the company is likely to have continued to ramp up its supply.
Interventional Oncology and Embolization is also expected to have delivered strong global growth, aided by demand for its broad range of technologies.
According to the Zacks Consensus Estimate, Cardiovascular revenues are expected to see a 0.7% decline from the prior-year period.
What Our Model Unveils for BSX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.
Earnings ESP: Boston Scientific has an Earnings ESP of -3.63%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Phibro Animal Health (PAHC - Free Report) has an Earnings ESP of +2.10% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2027 results soon.
PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2.
IDXX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company’s third-quarter EPS implies a jump of 9.1% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) , or BD, has an Earnings ESP of +3.28% and a Zacks Rank #2. The company will release its fourth-quarter fiscal 2026 results on Nov. 5.
BD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.